Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Accumulated Expenses (2016 - 2025)

Standard Biotools (LAB) has disclosed Accumulated Expenses for 15 consecutive years, with $30.7 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Expenses rose 46.24% to $30.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $30.7 million, a 46.24% increase, with the full-year FY2024 number at $30.7 million, up 46.24% from a year prior.
  • Accumulated Expenses was $30.7 million for Q4 2024 at Standard Biotools, up from $2.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $30.7 million in Q4 2024 to a low of $872000.0 in Q3 2023.
  • A 5-year average of $8.7 million and a median of $6.5 million in 2020 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 58.59% in 2021, then soared 191.4% in 2024.
  • Standard Biotools' Accumulated Expenses stood at $11.9 million in 2020, then plummeted by 58.59% to $4.9 million in 2021, then soared by 86.04% to $9.2 million in 2022, then surged by 129.64% to $21.0 million in 2023, then soared by 46.24% to $30.7 million in 2024.
  • Per Business Quant, the three most recent readings for LAB's Accumulated Expenses are $30.7 million (Q4 2024), $2.5 million (Q3 2024), and $3.7 million (Q2 2024).